Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 11/04/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

iShares Biotechnology ETF

IBB | ETF

$142.85

$7.63 B

0.56%

$0.80

0.45%

Vitals

YTD Return

5.3%

1 yr return

19.6%

3 Yr Avg Return

-3.8%

5 Yr Avg Return

5.7%

Net Assets

$7.63 B

Holdings in Top 10

62.5%

52 WEEK LOW AND HIGH

$142.8
$114.98
$149.47

Expenses

OPERATING FEES

Expense Ratio 0.45%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 46.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Exchange Traded Fund

Name

As of 11/04/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

iShares Biotechnology ETF

IBB | ETF

$142.85

$7.63 B

0.56%

$0.80

0.45%

IBB - Profile

Distributions

  • YTD Total Return 5.3%
  • 3 Yr Annualized Total Return -3.8%
  • 5 Yr Annualized Total Return 5.7%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.21%
DIVIDENDS
  • Dividend Yield 0.6%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    iShares Biotechnology ETF
  • Fund Family Name
    BlackRock-advised Funds
  • Inception Date
    Feb 05, 2001
  • Shares Outstanding
    64000000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Greg Savage

Fund Description

The Fund seeks to track the investment results of the NYSE Biotechnology Index (the “Underlying Index”), which measures the performance of U.S.-listed securities of companies that are classified according to the ICE Uniform Sector Classification schema within the Biotechnology Sub-Industry Group (as determined by ICE Data Indices, LLC or its affiliates (collectively “Index Provider” or “IDI”)) and that also meet other eligibility criteria determined by the Index Provider, including minimum market capitalization and liquidity requirements. Companies classified within the Biotechnology Sub-Industry Group include those companies that are engaged in the research and development of therapeutic treatments but that are not focused on the commercialization and mass production of pharmaceutical drugs. The Biotechnology Sub-Industry Group also includes those companies that are engaged in the production of tools or systems that enable biotechnology processes. The Underlying Index includes large-, mid- and small-
capitalization companies and may change over time. As of March 31, 2024, a significant portion of the Underlying Index is represented by securities of companies in the biotechnology and healthcare industries or sectors. The components of the Underlying Index are likely to change over time.
BFA uses an indexing approach to try to achieve the Fund’s investment objective. Unlike many investment companies, the Fund does not try to “beat” the index it tracks and does not seek temporary defensive positions when markets decline or appear overvalued.
Indexing may eliminate the chance that the Fund will substantially outperform the Underlying Index but also may reduce some of the risks of active management, such as poor security selection. Indexing seeks to achieve lower costs and better after-tax performance by aiming to keep portfolio turnover low in comparison to actively managed investment companies.
BFA uses a representative sampling indexing strategy to manage the Fund. “Representative sampling” is an indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to that of an applicable underlying index. The securities selected are expected to have, in the aggregate, investment characteristics (based on factors such as market capitalization and industry weightings), fundamental characteristics (such as return variability and yield) and liquidity measures similar to those of an applicable underlying index. The Fund may or may not hold all of the securities in the Underlying Index.
The Fund generally will invest at least 80% of its assets in the component securities of its Underlying Index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, including shares of money market funds advised by BFA or its affiliates, as well as in securities not included in the Underlying Index, but which BFA believes will help the Fund track the Underlying Index. Cash and cash equivalent investments associated with a derivative position will be treated as part of that position for the purposes of calculating the percentage of investments included in the Underlying Index. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund.
The Fund may lend securities representing up to one-third of the value of the Fund's total assets (including the value of any collateral received).
The Underlying Index is sponsored by the Index Provider, which is independent of the Fund and BFA. The Index Provider determines the composition and relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
Industry Concentration Policy. The Fund will concentrate its investments i.e., hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. For purposes of this limitation, securities of the U.S. government (including its agencies and instrumentalities) and repurchase agreements collateralized by U.S. government securities are not
considered to be issued by members of any industry.
Read More

IBB - Performance

Return Ranking - Trailing

Period IBB Return Category Return Low Category Return High Rank in Category (%)
YTD 5.3% -26.9% 24.4% 83.65%
1 Yr 19.6% -7.8% 49.2% 54.72%
3 Yr -3.8%* -32.5% 9.5% 80.92%
5 Yr 5.7%* -4.9% 13.7% 82.19%
10 Yr 4.1%* 0.1% 13.3% 90.09%

* Annualized

Return Ranking - Calendar

Period IBB Return Category Return Low Category Return High Rank in Category (%)
2023 3.5% -12.6% 19.0% 40.88%
2022 -14.0% -53.9% 3.2% 68.42%
2021 0.7% -39.6% 24.2% 47.37%
2020 25.7% -13.6% 178.2% 16.11%
2019 25.0% 3.8% 63.8% 24.81%

Total Return Ranking - Trailing

Period IBB Return Category Return Low Category Return High Rank in Category (%)
YTD 5.3% -26.9% 24.4% 83.65%
1 Yr 19.6% -7.8% 49.2% 54.72%
3 Yr -3.8%* -32.5% 9.5% 80.92%
5 Yr 5.7%* -4.9% 13.7% 82.19%
10 Yr 4.1%* 0.1% 13.3% 90.09%

* Annualized

Total Return Ranking - Calendar

Period IBB Return Category Return Low Category Return High Rank in Category (%)
2023 3.8% -12.6% 19.0% 57.86%
2022 -13.7% -53.9% 3.7% 76.32%
2021 1.0% -33.9% 26.0% 78.29%
2020 26.0% -0.7% 180.6% 36.91%
2019 25.2% 4.6% 63.8% 56.39%

IBB - Holdings

Concentration Analysis

IBB Category Low Category High IBB % Rank
Net Assets 7.63 B 6.87 M 47.2 B 9.43%
Number of Holdings 219 26 430 4.40%
Net Assets in Top 10 4.6 B 2.12 M 22.1 B 5.03%
Weighting of Top 10 62.48% 18.4% 79.7% 10.06%

Top 10 Holdings

  1. BlackRock Cash Funds: Institutional, SL Agency Shares 12.60%
  2. Regeneron Pharmaceuticals, Inc. 8.36%
  3. Gilead Sciences, Inc. 8.33%
  4. Vertex Pharmaceuticals, Inc. 8.02%
  5. Amgen, Inc. 7.96%
  6. Moderna, Inc. 4.03%
  7. IQVIA Holdings, Inc. 3.76%
  8. Biogen, Inc. 3.37%
  9. Alnylam Pharmaceuticals, Inc. 3.08%
  10. Mettler-Toledo International, Inc. 2.96%

Asset Allocation

Weighting Return Low Return High IBB % Rank
Stocks 		99.84% 87.34% 106.13% 14.47%
Cash 		12.82% 0.00% 33.01% 3.77%
Other 		0.00% -22.99% 23.24% 35.85%
Preferred Stocks 		0.00% 0.00% 7.86% 57.86%
Convertible Bonds 		0.00% 0.00% 0.37% 42.21%
Bonds 		0.00% 0.00% 12.39% 55.35%

Stock Sector Breakdown

Weighting Return Low Return High IBB % Rank
Healthcare 		100.00% 59.26% 100.00% 20.78%
Utilities 		0.00% 0.00% 0.00% 38.31%
Technology 		0.00% 0.00% 22.69% 42.21%
Real Estate 		0.00% 0.00% 5.89% 42.21%
Industrials 		0.00% 0.00% 7.02% 42.21%
Financial Services 		0.00% 0.00% 1.60% 55.19%
Energy 		0.00% 0.00% 0.00% 38.31%
Communication Services 		0.00% 0.00% 9.11% 41.56%
Consumer Defense 		0.00% 0.00% 25.73% 45.45%
Consumer Cyclical 		0.00% 0.00% 1.92% 42.21%
Basic Materials 		0.00% 0.00% 7.16% 58.44%

Stock Geographic Breakdown

Weighting Return Low Return High IBB % Rank
US 		99.84% 66.06% 104.41% 11.32%
Non US 		0.00% 0.00% 28.87% 78.62%

IBB - Expenses

Operational Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.45% 0.08% 4.48% 88.68%
Management Fee 0.45% 0.03% 1.25% 12.58%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 46.00% 0.00% 238.00% 44.44%

IBB - Distributions

Dividend Yield Analysis

IBB Category Low Category High IBB % Rank
Dividend Yield 0.56% 0.00% 6.24% 30.19%

Dividend Distribution Analysis

IBB Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annual Quarterly Annual

Net Income Ratio Analysis

IBB Category Low Category High IBB % Rank
Net Income Ratio 0.21% -2.54% 1.85% 25.00%

Capital Gain Distribution Analysis

IBB Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

IBB - Fund Manager Analysis

Managers

Greg Savage

Start Date

Tenure

Tenure Rank

Jan 01, 2008

14.42

14.4%

Greg Savage, Managing Director; has been associated with BlackRock Fund Advisors since 2009. Mr. Savage has been a senior portfolio manager for BFA and BTC since 2009. Prior to his employment with BFA and BTC, Mr. Savage was a senior portfolio manager from 2006 to 2009 for BGFA and BGI and a portfolio manager from 2001 to 2006 for BGFA and BGI.

Jennifer Hsui

Start Date

Tenure

Tenure Rank

Aug 01, 2012

9.84

9.8%

Jennifer Hsui, Managing Director & Portfolio Manager at BlackRock Investment Management LLC has been employed by BlackRock Fund Advisors as a senior portfolio manager since 2007. Prior to that, Ms. Hsui was a portfolio manager from 2006 to 2007 for BGFA. She was a research analyst for RBC Capital Markets from 2003 to 2006.

Amy Whitelaw

Start Date

Tenure

Tenure Rank

Aug 01, 2018

3.83

3.8%

Amy Whitelaw is Managing Director of BlackRock, Inc. since 2013 and was Director of the firm from 2009 to 2012. Ms. Whitelaw's service with the firm dates back to 1998, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Ms. Whitelaw served as Principal of BGI from 2000 to 2009. Previously Ms. Whitelaw worked in the Transition Services group as a transition manager and strategist, and was also an international equity trader on BGI’s trading desk.

Paul Whitehead

Start Date

Tenure

Tenure Rank

Jan 01, 2022

0.41

0.4%

Paul Whitehead is responsible for supporting the day-to-day management of the MML Blend Fund’s portfolio, including setting the Fund’s overall investment strategy and overseeing the management of the Fund. Mr. Whitehead is a Managing Director of BlackRock, Inc., Co-Head of Index Equity, and Co-Head of BlackRock’s ETF and Index Investments business. Mr. Whitehead also oversees the management of BlackRock’s Institutional and iShares funds. Mr. Whitehead was previously the Global Head of Equity Trading and the Global Head of Transition Management within BlackRock’s Global Trading Group. Mr. Whitehead’s service with the firm dates back to 1996, including his years with Barclays Global Investors, which merged with BlackRock in 2009. Prior to his current role, Mr. Whitehead was Head of Americas Equity Trading. Previously, he managed the trading team responsible for all Institutional Index funds, Exchange Traded funds, and Transition Management mandates. Mr. Whitehead represents BlackRock on the board of Luminex, a buy-side owned Alternative Trading System launched in 2015.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.88 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.